| Ticker Details |
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
|
| IPO Date: |
November 9, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.18B |
| Activated in VL: |
False |
| Average Daily Range |
| Avg Daily Range: |
$0.98 | 2.78%
|
| Avg Daily Range (30 D): |
$0.35 | 1.73%
|
| Avg Daily Range (90 D): |
$0.49 | 2.19%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.16M |
| Avg Daily Volume (30 D): |
1.62M |
| Avg Daily Volume (90 D): |
1.94M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
69 |
| Avg Trade Size (Sh.) (90 D): |
73 |
| Institutional Trades |
| Total Institutional Trades: |
8,038 |
| Avg Institutional Trade: |
$3.49M |
| Avg Institutional Trade (30 D): |
$5.83M |
| Avg Institutional Trade (90 D): |
$6M |
| Avg Institutional Trade Volume: |
.1M |
| Avg Institutional Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.62M |
| Avg Closing Trade (30 D): |
$10.75M |
| Avg Closing Trade (90 D): |
$12.35M |
| Avg Closing Volume: |
210.84K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q3 2025 |
|
Basic EPS
|
|
$.15
|
$1.71
|
|
Diluted EPS
|
|
$.15
|
$1.67
|
|
Revenue
|
|
$268.3M
|
$458.58M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
|
$18.66M
|
$215.72M
|
|
Operating Income / Loss
|
|
$26.47M
|
$223.18M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
|
$.13M
|
$109.14M
|
|
PE Ratio
|
|
|
|
|
|
|
